undamentalytics Newsletter
Sign in

Novavax Inc income statement

In fiscal 2025, Novavax Inc reported revenue of $1.12bn, up 64.7% on the year before, operating income of $453m (a 40.3% margin) and net income of $440m, or $2.58 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue01522213136153134194761,1461,9829846821,123414
Cost of revenue——————————009033442037389
Gross profit——————————4761,1461,0796404791,050325
Research and development28182759941632381681741147472,5351,235738391342340
Selling, general and administrative————————————489469337157121
General and administrative11111015203147343434145298—————
Operating income−38−22−30−52−84−157−269−172−174−121−417−1,687−645−567−249453−234
Interest expense0000001314141415212014202322
Income before tax−36−19−29−52−83−157———−133−418−1,715−654−543−177442−245
Income tax000000———0029421122
Net income−36−19−29−52−83−157−280−184−185−133−418−1,744−658−545−187440−248
Diluted EPS−$6.80−$3.40−$0.22−$6.20−$7.40−$12.00−$20.60−$12.56−$9.99−$5.51−$7.27−$23.44−$8.42−$5.41−$1.23$2.58−$1.49
Diluted shares (average)———8m——14m15m18m24m58m74m78m101m152m173m166m
EBITDA−37−20−28−50−79−152−261−164−167−115−412−1,674−616−526−201481−216

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MGTX vs NVAXMNKD vs NVAXNVAX vs SVA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Novavax Inc's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Novavax Inc.